SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases & Vaccines
- Oncology & Hematology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI®
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Global Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREIQVIA Careers
Featured Careers
Stay Connected
WE'RE HIRING
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESWhite Paper
Inflammatory Bowel Disease Therapeutics on the Rise
IQVIA Pipeline Link/ IQVIA Trial Link
Sep 17, 2025
The evolving pipeline and clinical trial landscape in ulcerative colitis and Crohn’s disease
Inflammatory bowel disease (IBD) refers to a group of conditions characterized by swelling and inflammation of the tissues in the digestive tract. It is an autoimmune disorder that typically appears as a sudden flare-up of symptoms. Most cases are diagnosed in individuals aged 35 years or younger, with a second peak of diagnosis occurring in individuals in their 60s.1 Globally, the highest rates of IBD prevalence and incidence are observed in Northern Europe and North America.
The 2 main types include ulcerative colitis (UC) and Crohn’s disease (CD). UC is an idiopathic inflammatory condition which is characterized by chronic inflammation of the colon, leading to diffuse friability, superficial erosions, and associated rectal bleeding. It is the most common form of IBD with a prevalence of 156 to 291 cases per 100,000 population and can affect any part of the large intestine. The primary symptom is bloody diarrhea, with or without mucus. Associated symptoms also include urgency or tenesmus, abdominal pain, malaise, weight loss, and fever.
CD most commonly affects the small intestine and proximal colon but can affect any part of the gastrointestinal tract from the mouth to the anus. The primary symptoms include persistent diarrhea, rectal bleeding and abdominal cramps.CD has a prevalence of 100 to 300 per 100,000 population. Compared to CD, UC has a higher prevalence in adults. In the paediatric population; however, UC is less prevalent than CD.
Current research highlights the following key areas in IBD pathogenesis: immune dysregulation; genetic alterations; microbiota imbalances; microbial infections; and links between IBD and other inflammatory conditions. These collectively lead to intestinal damage and chronic inflammation.
This white paper provides an update on current treatment options for UC and CD, outlining the latest developments including ongoing clinical trials of key experimental drugs with data sourced from IQVIA Pipeline Link and IQVIA Trial Link.
Explore the latest clinical trials and emerging therapies for ulcerative colitis and Crohn’s disease. This white paper reveals how IQVIA Pipeline Link and Trial Link support smarter IBD drug development decisions. Read now to uncover innovation and strategic insights in a fast-moving therapeutic space.